Comparative effectiveness of first-line ribociclib plus aromatase inhibitor versus palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer: A global real-world evidence study.
| Published in: | Journal of Clinical Oncology Vol. 44; pp. 45 - 85 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Published: |
American Society of Clinical Oncology
2026 Supplement 19
|
| Online Access: | View this record in EBSCOhost |